{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=102", "query": { "intervention": "SC", "page": 102 }, "page_size": 10 }, "pagination": { "page": 102, "page_size": 10, "total_count": 3868, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=103&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=101&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T10:56:17.502Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05032183", "title": "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Lymphoblastic Lymphoma", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tagraxofusp-erzs", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2022-02-17", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032183" }, { "nct_id": "NCT01194245", "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin lispro", "type": "DRUG" }, { "name": "recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Insulin glulisine", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2010-08", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 19, "location_summary": "Escondido, California • La Jolla, California • San Mateo, California + 16 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194245" }, { "nct_id": "NCT03351738", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stable Coronary Heart Disease" ], "interventions": [ { "name": "MEDI5884", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "45 Years to 80 Years" }, "enrollment_count": 133, "start_date": "2017-12-13", "completion_date": "2018-11-09", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 23, "location_summary": "Anniston, Alabama • Huntsville, Alabama • El Cajon, California + 20 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "El Cajon", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03351738" }, { "nct_id": "NCT05633355", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Rocatinlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 187, "start_date": "2023-01-30", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633355" }, { "nct_id": "NCT00807885", "title": "Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dehydration" ], "interventions": [ { "name": "hylenex-facilitated subcutaneous Lactated Ringer's infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxter Healthcare Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": "2008-12", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2011-10-26", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 2, "location_summary": "Lincoln, Nebraska • Neptune City, New Jersey", "locations": [ { "city": "Lincoln", "state": "Nebraska" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00807885" }, { "nct_id": "NCT01307618", "title": "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "NA17.A2 Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant MAGE-3.1 Antigen", "type": "BIOLOGICAL" }, { "name": "Recombinant Interleukin-12", "type": "BIOLOGICAL" }, { "name": "MART-1 Antigen", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307618" }, { "nct_id": "NCT02399917", "title": "Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Lirilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-04-20", "completion_date": "2018-07-12", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399917" }, { "nct_id": "NCT05039840", "title": "Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "SAR441344 IV", "type": "DRUG" }, { "name": "SAR441344 SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 109, "start_date": "2021-11-10", "completion_date": "2026-11-24", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 22, "location_summary": "Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more", "locations": [ { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039840" }, { "nct_id": "NCT06402513", "title": "A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Ravagalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2024-06-24", "completion_date": "2024-10-08", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06402513" }, { "nct_id": "NCT01776008", "title": "Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Positive", "HER2/Neu Negative", "Recurrent Breast Carcinoma", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Neoadjuvant Therapy", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2013-01", "completion_date": "2015-05-05", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-11-09T10:56:17.502Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01776008" } ] }